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A SIMPLE AND CHEAPER IN HOUSE VARICELLA ZOSTER VIRUS ANTIBODY INDIRECT ELISA
Erika ONO(1), Manuel Mindlin LAFER(1), Lily Yin WECKX(1), Celso GRANATO(2,3) & Maria Isabel de MORAES-PINTO(1)
SUMMARY
We have developed a cheaper an simple in house indirect ELISA that uses the live attenuated VZV vaccine as a coating antigen.
The alternative ELISA had an agreement of 94% when compared with a commercial VZV ELISA kit. Moreover, our ELISA
proved to be more reliable than the kit when assessing true negative samples.
By adding a standard serum, we were able to produce results in international units per millilitre. Also, the addition of an extra step
with 8M urea allowed the assessment of VZV IgG avidity without excessive costs.
The cost per sample to test VZV IgG was 2.7 times cheaper with our ELISA, allowing the testing of many samples without the
burden of production of VZV antigen in the laboratory.
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INTRODUCTION
Assessment of varicella zoster virus (VZV) antibodies is performed
routinely by enzyme immunoassays (ELISA) with commercially
available kits. A cheaper and as accurate alternative is the use of “in
house” ELISAs. However, that requires the production of VZV antigen
in tissue culture and its subsequent extraction from VZV-infected cells.
Moreover, most in house ELISAs use a control for nonspecific antibody
binding, a similarly prepared extract of uninfected cells14.
Production of VZV antigen is usually performed in cell lines derived
from human fibroblasts (e.g., MRC5 cell line), known to be time
consuming and very often not so easy to handle21.
The increasing use of a VZV vaccine in different populations has
added to the necessity of measuring anti-VZV antibodies as an indicator
of prior or recurrent infection, to predict susceptibility to disease, and to
evaluate immune response to vaccination3,4,5,10,12,16,17,18,22,23.
We have developed a cheaper and simple alternative indirect ELISA
that uses the live attenuated VZV vaccine as a coating antigen. The use
of a standard reference serum allowed us to produce results in
international units per millilitre (IU/mL). Finally, with the addition of
an extra step with 8M urea, we could also assess VZV IgG avidity.
MATERIAL AND METHODS
Serum samples: Two hundred and thirty-nine serum samples were
tested: 221 were from healthy adults, 122 (55%) of them who referred
having had varicella in the past and 99 (45%) who denied previous clinical
VZV infection; the remaining 18 sera were drawn from 12-month-old
infants without clinical or serologic evidence of previous VZV infection.
Serum samples were collected to investigate VZV seroprevalence in
different populations. All studies were approved by the Ethics Committee
of the Federal University of São Paulo, in São Paulo, Brazil.
VZV ELISA kit: A Hemagen indirect ELISA kit to detect IgG VZV
antibodies (Columbia, USA) was used according to the manufacturer’s
instructions.
High, medium and low callibrators were added together with serum
samples diluted 1 in 41, all in duplicates. A standard curve with a
corresponding linear regression curve fit equation was obtained and
results were calculated by interpolation of mean optical density (OD)
values onto the curve fit.
Results were considered positive if they were higher than 20 arbitrary
units per millilitre (AU/mL), as suggested by the kit’s manufacturer.
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“In House” VZV indirect ELISA: Varicella IgG antibodies were
assessed by an “in house” indirect ELISA. Immulon 2 96-well microtiter
plates (Dynex, USA) were coated with varicella vaccine batch
VA254A41A, 103,3 PFU/mL (Varilrix, SmithKline Beecham, Belgium)
diluted 1:100 in 0.1M carbonate-bicarbonate buffer, pH 9.6, and
incubated overnight at 4 °C. Two-fold serial dilutions of serum samples
and of varicella reference serum [in house standard calibrated against
“Varicella zoster virus antibody human immunoglobulin- NIBSC reagent
(90/690)”] in 0.01M phosphate buffered saline (PBS), pH 7.2 and 0.05%
Tween 20 with 1% bovine serum albumin (BSA) were added to the plate
and incubated for 1 h at 37 °C. Reference serum was added to 10 wells
and serum samples were added to 3 wells, in all twofold dilutions starting
at 1:100.
In the next step, alkaline phosphatase conjugated rabbit anti-human
IgG, specific for γ-chains (Dako, Denmark) diluted 1:500 in 0.01M PBS,
pH 7.2 and 0.05% Tween 20, was incubated for 1 h at 37 °C. p-
nitrophenyl-phosphate disodium (Sigma, USA) in 0.1M diethanolamine,
0.005M magnesium chloride buffer, pH 9.8, was used as substrate in a
concentration of 1 mg/mL. OD was read at 405 nm in an immunoreader
ELX-800, using 630 nm as a reference filter (Bio-Tek Instruments, USA).
Between steps, the plate was washed five times in 0.01M PBS, pH
7.2 and 0.05% Tween 20. All solutions were added in a 100 µL volume
to microplate wells. Varicella zoster antibodies were expressed in IU/
mL using the curve comparison method to transform optical density in
concentration units. In all plates two blank wells we always present, and
mean values were subtracted from all other wells.
IgG antibody avidity: To assess varicella IgG avidity, an extra step
was added to the test. An 8M urea solution in PBS was dispensed to half
of all wells after serum samples had been washed out. IgG avidity index
was calculated by dividing results obtained with urea addition by results
without urea and multiplying them by 100. Serum samples with avidity
indices below 30% were considered with low avidity.
Protective antibody levels: Because an internationally accepted
antibody level that predicts previous contact with wild varicella zoster
virus or vaccine is not available, we have established a cutoff based on
the following. Nineteen children who had been regularly followed up
from birth and did not have evidence of previous varicella infection
assessed both by clinical exam and repeated serologic testing during the
first year of life were tested for varicella at 12 months of age. Cutoff of
0.2 IU/mL was calculated by adding mean antibody levels (0.04 IU/mL)
to 3 standard deviations (3 x 0.04 IU/mL).
Assessment of VZV ELISA specificity: Because cross-reactivity
among Herpesvirus antibodies has been described1,2, we have tested 8
serum samples for cytomegalovirus (CMV) IgG (CMV-IgG, Asxym,
Immunofluorimetry with microparticles) and Epstein Barr viral capsid
antigen (VCA) IgG (Indirect Immunofluorescence, “home made” with
H3PR1 cells). Five sera were from adults without history of VZV
infection who proved to be seronegative for IgG VZV by our “in house
ELISA”; the other 3 sera were from 15 month old infants who had been
vaccinated at 12 month of age with VZV vaccine (Varilrix, SmithKline
Beecham, Belgium) and were seropositive for IgG by our “in house”
VZV ELISA.
RESULTS
Comparison of “in house” ELISA with commercial ELISA kit: In
house ELISA and commercial ELISA kit showed an agreement of 94%.
When compared with commercial kit, our in house ELISA showed a
sensitivity of 95% and specifity of 87%. Only 13 out of 239 samples tested
produced discordant results when assessed by both ELISAs (Table 1).
True positive and true negative samples assessed by “in house”
ELISA and commercial ELISA kit: As described in the Materials and
Methods session, we sellected among the samples tested by both methods
those that were supposedly positive (adults who referred previous clinical
VZV infection) and those that were supposedly negative (12-month
infants without clinical and laboratory evidence of VZV infection).
While the commercial ELISA kit detected 98% (120 in 122)
supposedly positive samples and 89% (16 in 18) supposedly negative
samples, our in house ELISA detected 98% (120 in 122) and 100% (18
in 18) of the same serum samples (Table 2).
Assessment of VZV ELISA specifity: Among the 5 samples from
VZV IgG seronegative adults, 4 were positive from CMV IgG and one
was negative. All 5 sera were also positive for VCA IgG antibodies.
Among the 3 samples from VZV IgG seropositive children, 2 were
seronegative for CMV IgG and one was positive; 2 were seronegative
for VCA IgG and one was weakly positive (Table 3).
Cost assessment of “in house” ELISA and commercial ELISA
kit: Our in house ELISA proved to be cheaper than the commercial kit,
with a cost per sample of US$0.99 and US$2.70, respectively
(Table 4).
Table 1
Relative performance of in house indirect ELISA in detecting varicella zoster
IgG antibodies on the basis of a commercial indirect ELISA
Commercial Kit of indirect ELISA
Positive Negative Total
In house Positive 172 08 180
indirect ELISA Negative 005 54 059
Total 177 62 239
Sensitivity: 97%; Specificity: 87%; Agreement: 94%
Table 2
Relative performance of in house indirect ELISA and a commercial kit of
indirect ELISA in detecting varicella zoster antibodies in samples from
individuals with previous varicella infection and in children without previous
varicella infection at 12 months of age
Samples In house ELISA Commercial Kit
Supposedly positive  120/122 (98%)  120/122 (98%)
(previous varicella infection)
Supposedly negative  18/18 (100%)  16/18 (89%)
(12 months of age without
history of varicella infection)
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IgG VZV antibody avidity: By the addition of an extra 8M urea
step, we were able to assess IgG VZV antibody avidity using the in
house ELISA. As shown on Table 5, individuals with past primary VZV
infection had high (above 60%) or intermediate IgG avidity (between
30% and 60%). Those with recent or concurrent infection showed low
IgG avidity (below 30%).
DISCUSSION
We have developed a modified indirect ELISA that proved to be
simple, cheap and easy to perform. Most “in house” ELISAs that detect
antibodies against viruses require the production and extraction of virus
antigen6,20. Many laboratories do not have tissue culture facilities,
precluding the use of such techniques.
However, previous immunoassays well accepted in the literature have
used alternatives for less accessible reagents. In special, toxoid vaccines
have been routinely used in ELISAs to detect tetanus and diphtheria
antibodies6-9,15.
Live attenuated vaccines against measles and mumps have also been
used as antigens for “in vitro” T cell proliferation assays, with good
results11.
Our modified ELISA had a good agreement when compared with a
commercial ELISA kit and did not show cross-reactivity with antibodies
from other Herpesviruses. Moreover, it proved to be superior than the
kit when true negative samples were tested. As suggested by others19,
we used sera from 12 month-old infants without evidence of previous
VZV infection.
Another advantage of the test we have developed was the use of a
reference serum with a known concentration antibodies measured in IU/
mL. As it is well known, that allows the comparison of results obtained
in different countries13.
Finally, introducing an extra step allowed the assessment of VZV
IgG avidity without excessive costs.
In sum, we have developed a cheap and accurate alternative ELISA
to measure VZV antibodies that proved suitable for most laboratories
without the cumbersome needs of tissue culture, that produced results in
IU/mL and permitted the assess of IgG avidity.
RESUMO
Desenvolvimento de ELISA indireto simples e de baixo custo para
detecção de anticorpos anti-varicela zoster
Desenvolvemos um ensaio imunoenzimático (ELISA) indireto
simples e econômico para detecção de anticorpos contra o vírus da
varicela zoster (VVZ) que utiliza a vacina contendo o vírus vivo atenuado
como antígeno para recobrir a placa.
Este ELISA mostrou uma concordância de 94% quando comparado
com um kit de ELISA comercial para anticorpos contra varicela. Além
disso, nosso ELISA mostrou ser mais confiável que o kit quando amostras
comprovadamente negativas foram testadas.
O uso de um soro padrão de referência, calibrado em unidades
internacionais por mililitro, possibilitou também que os resultados
pudessem ser comparados com outros estudos. O acréscimo de uma etapa
extra com solução de uréia 8M permitiu avaliação de avidez de IgG para
VVZ sem custos excessivos.
O custo por amostra para testar IgG contra VVZ com nosso ELISA
foi 2,7 vezes mais barato quando comparado com o kit comercial.
Table 3
 Assessment of cross-reactivity between VZV IgG antibodies detected by our
ELISA and cytomegalovirus (CMV) IgG and Epstein Barr viral capsid
antigen (VCA) IgG
VZV IgG antibodies CMV IgG VCA IgG
Negative (n = 5) 4 positive 5 positive
1 negative 0 negative
Positive (n = 3)* 2 negative 2 negative
1 positive 1 weakly positive
* Serum sample tested positive for CMV IgG was not the same tested weakly
positive for Epstein Barr VCA IgG.
Table 4
Compared costs of varicella zoster in house indirect ELISA and
commercial Kit
Costs and sample In house Commercial
tested per microplate ELISA kit
Cost per microplate US$ 27.67 US$ 243.33
Number of sample per microplate 28 90
Cost per sample US$ 0.99 US$ 2.70
Table 5
IgG VZV antibody avidity assessed in different patients
Patient VZV antibodies VZV IgG
(IU/mL) avidity (%)
Adult A with VZV 1.4 62
infection in childhood
Adult B with VZV 1.1 48
infection in childhood
Adult C with concurrent 1.1 62
herpes zoster infection
Child A with concurrent 11.1 1.3
VZV infection
Child B 2 months 3.2 6.1
after infection VZV
168
ONO, E.; LAFER, M.M.; WECKX, L.Y.; GRANATO, C. & MORAES-PINTO, M.I. - A simple and cheaper in house varicella zoster virus antibody indirect ELISA. Rev. Inst. Med. trop. S.
Paulo, 46(3):165-168, 2004.
REFERENCES
1. AMERICAN ACADEMY OF PEDIATRICS - Human Herpesvirus 6 (including Roseola)
and 7. In: PICKERING, L.K., ed. Red Book: 2003 Report of the Committee on
Infectious Diseases. 26. ed. Elk Grove Village, American Academy of Pediatrics,
2003. p. 357-358.
2. AMERICAN ACADEMY OF PEDIATRICS - Varicella-zoster infections. In:
PICKERING, L.K., ed. Red Book: 2003 Report of the Committee on Infectious
Diseases. 26. ed. Elk Grove Village, American Academy of Pediatrics, 2003. p. 672-
686.
3. AMPOFO, K.; SAIMAN, L.; LARUSSA, P. et al. - Persistence of immunity to live
attenuated varicella vaccine in healthy adults. Clin. infect. Dis., 34: 774-779, 2002.
4. ASANO, Y.; SUGA, S.; YOSHIKAWA, T. et al. - Experience and reason: twenty-year
follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics,
94: 524-526, 1994.
5. BOGGER-GOREN, S.; BABA, K.; HURLEY, P. et al. - Antibody response to varicella-
zoster virus after natural or vaccine-induced infection. J. infect. Dis., 146: 260-265,
1982.
6. DE MORAES-PINTO, M.I.; ORUAMABO, R.S.; IGBAGIRI, F.P. et al. - Neonatal tetanus
despite immunization and protective antitoxin antibody. J. infect. Dis., 171: 1076-
1077, 1995.
7. DE MORAES-PINTO, M.I.; ALMEIDA, A.C.M.; KENJ, G. et al. - Placental transfer
and maternally acquired neonatal IgG immunity in human immunodeficiency virus
infection. J. infect. Dis., 173: 1077-1084; 1996.
8. GALAZKA, A.M. - The immunological basis for immunization series. Module 2:
Diphtheria. Geneva, World Health Organization, 1993.
9. GALAZKA, A.M. - The immunological basis for immunization series. Module 3: Tetanus.
Geneva, World Health Organization, 1993.
10. GALIL, K.; LEE, B.; STRINE, T. et al. – Outbreak of varicella at a day-care center
despite vaccination. New Engl. J. Med., 347: 1909-1915, 2002.
11. GANS, H.; YASUKAWA, L.; RINKI, M. et al. - Immune responses to measles and
mumps vaccination of infants at 6, 9 and 12 months. J. infect. Dis., 184: 817-826,
2001.
12. GERSHON, A.A.; STEINBERG, S.P. & GELB, L. - Live attenuated varicella vaccine
use in immunocompromised children and adults. Pediatrics, 78: 757-762, 1986.
13. KEMENY, D.M. - Quantitation. In:___________ A pratical guide to ELISA. Oxford,
Pergamon, 1991. p. 57-67.
14. KRAH, D.L. - Assays for antibodies to varicella-zoster virus. Infect. Dis. Clin. N. Amer.,
10: 507-527, 1996.
15. KRISTIANSEN, M.; AGGERBECK, H. & HERON, I. - Improved ELISA for
determination of anti-diphtheria and/or anti-tetanus antitoxin antibodies in sera. Acta
path. microbiol. immunol. scand., 105: 843-853, 1997.
16. KUTER, B.; MATTHEWS, H.; SHINEFIELD, H. et al. - Ten year follow-up of healthy
children who received one or two injections of varicella vaccine. Pediat. infect. Dis.
J., 23: 132-137, 2004.
17. LEVIN, M.J.; GERSHON, A.A.; WEINBERG, A. et al. - Immunization of HIV-infected
children with varicella vaccine. J. Pediat., 139: 305-310, 2001.
18. REIS, A.D.; PANNUTI, C.S. & SOUZA, V.A.U.F. - Prevalência de anticorpos para o
vírus da varicela-zoster em adultos jovens de diferentes regiões climáticas brasileiras.
Rev. Soc. bras. Med. trop., 36: 317-320, 2003.
19. ROBERTSON, P.W.; BELL, S.M. & FERSON, M.J. - A method for determining the cut-
off value of a varicella-zoster virus IgG enzyme immunoassay for immune status. J.
virol. Meth., 26: 115-118, 1989.
20. SHANLEY, J.; MYERS, M.; EDMOND, B. & STEELE, R. - Enzyme-linked
immunosorbent assay for detection of antibody to varicella-zoster virus. J. clin.
Microbiol., 15: 208-211, 1982.
21. SHEHAB, Z. & BRUNELL, P.A. - Enzyme-linked immunosorbent assay for susceptibility
to varicella. J. infect. Dis., 148: 472-476, 1983.
22. WATSON, B.; KELLER, P.M.; ELLIS, R.W. & STARR, S.E. - Cell-mediated immune
responses after immunization of healthy seronegative children with varicella vaccine:
kinetics and specificity. J. infect. Dis., 162: 794-799, 1990.
23. ZERBONI, L.; NADER, S.; AOKI, K. & ARVIN, A.M. - Analysis of the persistence of
humoral and cellular immunity in children and adults immunized with varicella
vaccine. J. infect. Dis., 177: 1701-1704, 1998.
Received: 5 January 2004
Accepted: 14 May 2004
